References
- Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006;119:71.e1-8. https://doi.org/10.1016/j.amjmed.2006.05.001
- Renneboog B, Decaux G. Determination of threshold for attention and gait deficits encountered in chronic hyponatremia [Abstract]. J Am Soc Nephrol 2006;17:37A.
- Schrier RW. Does 'asymptomatic hyponatremia' exist? Nat Rev Nephrol 2010;6:185.
- Lien YH, Shapiro JI. Hyponatremia: clinical diagnosis and management. Am J Med 2007;120:653-658. https://doi.org/10.1016/j.amjmed.2006.09.031
- Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(11 Suppl 1):S1-S21.
- Decaux G, Soupart A. Treatment of symptomatic hyponatremia. Am J Med Sci 2003;326:25-30. https://doi.org/10.1097/00000441-200307000-00004
- Ellison DH, Berl T. Clinical practice: the syndrome of inappropriate antidiuresis. N Engl J Med 2007;356:2064-2072. https://doi.org/10.1056/NEJMcp066837
- Cox M, Guzzo J, Morrison G, Singer I. Demeclocycline and therapy of hyponatremia. Ann Intern Med 1977;86:113-114. https://doi.org/10.7326/0003-4819-86-1-113
- Curtis NJ, van Heyningen C, Turner JJ. Irreversible nephrotoxicity from demeclocycline in the treatment of hyponatremia. Age Ageing 2002;31:151-152. https://doi.org/10.1093/ageing/31.2.151
- White MG, Fetner CD. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with lithium carbonate. N Engl J Med 1975;292:390-392. https://doi.org/10.1056/NEJM197502202920803
- Decaux G, Genette F. Urea for long-term treatment of syndrome of inappropriate secretion of antidiuretic hormone. Br Med J 1981;283:1081-1083. https://doi.org/10.1136/bmj.283.6299.1081
- Schrier RW, Gross P, Gheorghiade M. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112. https://doi.org/10.1056/NEJMoa065181
- Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21:705-712. https://doi.org/10.1681/ASN.2009080857
- Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007;27:447-457. https://doi.org/10.1159/000106456
- Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 2007;297:1319-1331. https://doi.org/10.1001/jama.297.12.1319
- Greenberg A, Lehrich RW. Treatment of chronic hyponatremia: now we know how, but do we know when or if? J Am Soc Nephrol 2010;21:552-555. https://doi.org/10.1681/ASN.2010020157
- Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008;371:1624-1632. https://doi.org/10.1016/S0140-6736(08)60695-9